Early postoperative intraperitoneal adriamycin as an adjuvant treatment for advanced gastric cancer with lymph node or serosal invasion.
Early postop intraperitoneal adriamycin may be a excellent adjuvant treatment, which, when combined with the R2 gastric resection, may markedly improve the survival of patients with gastric cancer. Even if its only effect were to decrease the local recurrence rates, a markedly improved quality of life for gastric cancer patients would be achieved. We suggest that these improved local treatments should be combined with aggressive systemic therapy in order to develop an optimal adjuvant approach to the treatment of gastric cancer.